KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Amortization of Deferred Charges (2019 - 2025)

Historic Amortization of Deferred Charges for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $445000.0.

  • GoodRx Holdings' Amortization of Deferred Charges rose 774.82% to $445000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 4056.18%. This contributed to the annual value of $2.5 million for FY2024, which is 2616.79% down from last year.
  • According to the latest figures from Q3 2025, GoodRx Holdings' Amortization of Deferred Charges is $445000.0, which was up 774.82% from $439000.0 recorded in Q2 2025.
  • In the past 5 years, GoodRx Holdings' Amortization of Deferred Charges registered a high of $864000.0 during Q2 2021, and its lowest value of $413000.0 during Q3 2024.
  • In the last 5 years, GoodRx Holdings' Amortization of Deferred Charges had a median value of $846000.0 in 2023 and averaged $739526.3.
  • In the last 5 years, GoodRx Holdings' Amortization of Deferred Charges surged by 1021.71% in 2021 and then crashed by 5106.64% in 2024.
  • GoodRx Holdings' Amortization of Deferred Charges (Quarter) stood at $859000.0 in 2021, then dropped by 0.93% to $851000.0 in 2022, then fell by 0.94% to $843000.0 in 2023, then tumbled by 50.06% to $421000.0 in 2024, then grew by 5.7% to $445000.0 in 2025.
  • Its last three reported values are $445000.0 in Q3 2025, $439000.0 for Q2 2025, and $430000.0 during Q1 2025.